Entellus Medical (ENTL) Cut to Strong Sell at BidaskClub
Entellus Medical (NASDAQ:ENTL) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Tuesday.
Other research analysts also recently issued research reports about the stock. Canaccord Genuity reissued a “hold” rating and issued a $17.00 target price on shares of Entellus Medical in a research note on Tuesday, October 17th. TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a research note on Thursday, December 14th. William Blair downgraded shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, December 8th. ValuEngine upgraded Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a report on Tuesday. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $19.25.
Shares of Entellus Medical (NASDAQ ENTL) traded up $0.02 during mid-day trading on Tuesday, reaching $24.09. 89,300 shares of the company traded hands, compared to its average volume of 223,082. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $25.58. The firm has a market cap of $617.35, a P/E ratio of -18.67 and a beta of 0.02. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32.
Entellus Medical (NASDAQ:ENTL) last announced its earnings results on Wednesday, November 1st. The medical technology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.02. Entellus Medical had a negative net margin of 31.24% and a negative return on equity of 47.37%. sell-side analysts predict that Entellus Medical will post -1.33 EPS for the current year.
In other news, VP Kevin L. Mensink sold 2,500 shares of the business’s stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $19.00, for a total transaction of $47,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Thomas P. Williamson sold 2,449 shares of the business’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $24.08, for a total value of $58,971.92. The disclosure for this sale can be found here. Insiders sold a total of 111,442 shares of company stock valued at $2,647,158 in the last 90 days. 7.70% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of ENTL. Schwab Charles Investment Management Inc. grew its holdings in shares of Entellus Medical by 33.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 37,799 shares of the medical technology company’s stock worth $626,000 after purchasing an additional 9,469 shares during the period. Rhumbline Advisers purchased a new stake in shares of Entellus Medical during the 2nd quarter worth about $199,000. Bank of New York Mellon Corp grew its holdings in shares of Entellus Medical by 29.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 40,783 shares of the medical technology company’s stock worth $675,000 after purchasing an additional 9,270 shares during the period. Neuberger Berman Group LLC purchased a new stake in shares of Entellus Medical during the 2nd quarter worth about $381,000. Finally, Teachers Advisors LLC grew its holdings in shares of Entellus Medical by 76.5% during the 2nd quarter. Teachers Advisors LLC now owns 21,836 shares of the medical technology company’s stock worth $362,000 after purchasing an additional 9,467 shares during the period. Institutional investors and hedge funds own 78.24% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/entellus-medical-entl-cut-to-strong-sell-at-bidaskclub/1812260.html.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.